Anti-IL4/13

Question 1

Mechanism of action

Answer 1

Blocks binding of IL-4 to reduce eosinophil trafficking and IgE reactions while also blocking IL-13 to reduce mucus secretion and airway remodeling

Question 2

Dupilumab brand name

Answer 2

Dupixent

Question 3

Dupilumab dosage form

Answer 3

Injection

Question 4

Dupilumab age range

Answer 4

12 and up

Question 5

Dupilumab AE and Clinical Pearls

Answer 5

AE: injection site reactions, antibody development, arthralgias, conjunctivits
Precaution: anaphylaxis
Available in pre-filled syringe for in-office or at-home administration
Indicated as an add-on maintenance treatment in patients with moderate to severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma